Gland Pharma Ltd
GLANDGland Pharma Ltd
GLAND![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
38.60 | 3.75 | 1.10% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
44.06 | 6.22 | 0.55% |
Forecast & Ratings
Detailed Forecastfrom 10 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,384.63 | 1,512.74 | 1,668.73 | 2,129.76 | 2,772.41 | 3,597.66 | 4,624.65 | 3,865.06 | 5,834.96 | 5,834.97 | ||||||||||
Raw Materials | 530.72 | 463.36 | 727.42 | 971.18 | 1,108.93 | 1,765.36 | 2,072.53 | 1,732.34 | 4,331.65 | 4,331.66 | ||||||||||
Power & Fuel Cost | 46.96 | 49.24 | 60.35 | 74.03 | 78.50 | 74.59 | 95.05 | 124.84 | ||||||||||||
Employee Cost | 131.30 | 153.42 | 179.08 | 222.95 | 277.66 | 311.36 | 338.57 | 403.26 | ||||||||||||
Selling & Administrative Expenses | 53.92 | 74.75 | 108.29 | 82.52 | 98.54 | 128.48 | 177.92 | 187.93 | ||||||||||||
Operating & Other expenses | 82.74 | 113.42 | 9.69 | 7.22 | 114.15 | -119.14 | 206.49 | 207.92 | ||||||||||||
EBITDA | 538.99 | 658.55 | 583.90 | 771.86 | 1,094.63 | 1,437.01 | 1,734.09 | 1,208.77 | 1,503.31 | 1,503.31 | ||||||||||
Depreciation/Amortization | 63.46 | 74.15 | 78.21 | 81.96 | 94.59 | 98.78 | 110.30 | 146.74 | 344.57 | 344.57 | ||||||||||
PBIT | 475.53 | 584.40 | 505.69 | 689.90 | 1,000.04 | 1,338.23 | 1,623.79 | 1,062.03 | 1,158.74 | 1,158.74 | ||||||||||
Interest & Other Items | 16.42 | 6.39 | 4.13 | 3.56 | 7.18 | 3.41 | 5.24 | 7.45 | 26.20 | 26.21 | ||||||||||
PBT | 459.11 | 578.01 | 501.56 | 686.34 | 992.86 | 1,334.82 | 1,618.55 | 1,054.58 | 1,132.54 | 1,132.53 | ||||||||||
Taxes & Other Items | 145.51 | 164.29 | 180.44 | 234.45 | 220.01 | 337.85 | 406.89 | 273.54 | 360.08 | 360.08 | ||||||||||
Net Income | 313.60 | 413.72 | 321.12 | 451.89 | 772.85 | 996.97 | 1,211.66 | 781.04 | 772.46 | 772.45 | ||||||||||
EPS | 20.12 | 26.70 | 20.72 | 29.16 | 49.88 | 62.60 | 73.91 | 47.48 | 46.90 | 46.90 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Gland Pharma Ltd | 38.60 | 3.75 | 1.10% |
Sun Pharmaceutical Industries Ltd | 39.03 | 6.30 | 0.87% |
Cipla Ltd | 29.01 | 5.04 | 0.88% |
Zydus Lifesciences Ltd | 29.64 | 5.81 | 0.27% |
Price Comparison
Compare GLAND with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.67%
Top 5 Mutual Funds holding Gland Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.8269% | Percentage of the fund’s portfolio invested in the stock 1.29% | Change in the portfolio weight of the stock over the last 3 months 0.55% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/76 (+3) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9443% | Percentage of the fund’s portfolio invested in the stock 1.64% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/104 (0) |
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2342% | Percentage of the fund’s portfolio invested in the stock 1.57% | Change in the portfolio weight of the stock over the last 3 months -0.14% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/88 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹20.00
Ex DateEx Date
Aug 16, 2024
Past Dividends
No past dividends are available
News & Opinions
Stock alert: Indus Towers, Gland Pharma, Advanced Enzyme, DMart, Sapphire Foods
2 weeks ago•Business Standard
Gland Pharma promoter Fosun divests 6% stake for Rs 1,754 cr via bulk deal
2 weeks ago•Business Standard
Gland Pharma Promoter Offloads Stake Worth Rs 1,754
2 weeks ago•Bloomberg Quint
Fosun To Pare 5% Stake In Gland Pharma For $172 Million
2 weeks ago•Bloomberg Quint
Gland Pharma Ltd gains for fifth session
3 weeks ago•Business Standard
Gland Pharma Shares Rise The Most In Nine Months As Profit More Than Doubles
1 month ago•Bloomberg Quint
News Video
Sensex Flat, Nifty Tests 22,600; Gland Pharma Soars 8%, Sun Pharma Drops 3% | Opening Bell
1 month ago•ET NOW
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 22.33%, vs industry avg of 9%
Increasing Market Share
Over the last 5 years, market share increased from 0.96% to 1.62%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.32%, vs industry avg of 15.09%